Nayak Nirmal G, Modi Panthi, Shah Swasti, Patel Pranjal, Devangkumar Patel Devarshi, Rohitbhai Patel Riddhi, Hapani Devanshi
Public Health Dentistry, Karnavati School of Dentistry, Gandhinagar, IND.
Dentistry, AMC Dental College & Hospital, Ahmedabad, IND.
Cureus. 2023 Jun 14;15(6):e40403. doi: 10.7759/cureus.40403. eCollection 2023 Jun.
Background The oral condition known as recurrent aphthous ulceration (RAU) or recurrent aphthous stomatitis (RAS) is very prevalent. Its etiopathogenesis is unknown; hence, symptomatic therapy is all that can be offered if it manifests clinically. Lesion care aims to minimize discomfort and the frequency of relapses by bringing active illness under local control in the affected area. The current treatment options that may have negative side effects include the use of topical and systemic steroids, antibiotics, cauterization, and laser therapy. Objectives and Importance This study aimed to compare the efficiency of HiOra SG gel with triamcinolone acetonide gel in the management of RAS. Materials and Methods Fifty individuals with RAS were recruited for the trial and randomly assigned to either group I (HiOra SG gel) or group II (0.1% triamcinolone acetonide ointment; Oraways). After each meal for a total of 10 days, those with mouth ulcers were instructed to topically administer the drugs. The clinical data were analyzed by comparing the ulcer severity scores from the first, fifth, and 10th days. Results There was a statistically significant (p = 0.001) reduction in reported pain, pain duration, and overall ulcer severity across all groups. After therapy, however, neither the HiOra gel group nor the triamcinolone group showed any discernible improvement over the other. Conclusion The present study's findings corroborate the efficacy of HiOra SG gel in the treatment of RAS when compared to triamcinolone acetonide gel (0.1%). In this trial, no patients had any negative reactions to HiOra SG gel. In the future, further studies are needed with larger samples to prove its benefits.
背景 被称为复发性阿弗他溃疡(RAU)或复发性阿弗他口炎(RAS)的口腔疾病非常普遍。其发病机制尚不清楚;因此,如果临床上出现症状,只能提供对症治疗。病变护理旨在通过在受影响区域对活动性疾病进行局部控制,将不适和复发频率降至最低。目前可能有负面副作用的治疗选择包括使用局部和全身类固醇、抗生素、烧灼术和激光治疗。
目的和重要性 本研究旨在比较HiOra SG凝胶与曲安奈德凝胶治疗RAS的疗效。
材料和方法 招募了50名患有RAS的个体进行试验,并随机分为I组(HiOra SG凝胶)或II组(0.1%曲安奈德软膏;Oraways)。在总共10天的每餐饭后,指示患有口腔溃疡的人局部使用药物。通过比较第1、5和10天的溃疡严重程度评分来分析临床数据。
结果 所有组报告的疼痛、疼痛持续时间和总体溃疡严重程度均有统计学显著降低(p = 0.001)。然而,治疗后,HiOra凝胶组和曲安奈德组均未显示出比另一组有任何明显改善。
结论 与0.1%曲安奈德凝胶相比,本研究结果证实了HiOra SG凝胶治疗RAS的疗效。在该试验中,没有患者对HiOra SG凝胶有任何不良反应。未来,需要进行更大样本量的进一步研究以证明其益处。